Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs

Vet Rec. 2007 Sep 29;161(13):444-7. doi: 10.1136/vr.161.13.444.


Maropitant is a neurokinin-1 inhibitor that acts to prevent and treat vomiting by blocking stimuli to the final common pathway in the emetic centre of the brain. The field efficacy and safety of a single oral dose of maropitant were investigated for the prevention of vomiting in dogs with a history of motion sickness resulting from transportation by car in two blinded, placebo-controlled studies. In an exploratory study designed as a two-way crossover trial with 17 dogs, 10 of the dogs given the placebo vomited during a car journey but only three of the dogs vomited under maropitant treatment. In a larger multicentred parallel design study, 69 of 105 dogs treated with the placebo vomited during the journey compared with 15 of 106 dogs treated with maropitant (P < 0.0001).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Antiemetics / therapeutic use*
  • Cross-Over Studies
  • Dog Diseases / prevention & control*
  • Dogs
  • Double-Blind Method
  • Female
  • Male
  • Motion Sickness / prevention & control
  • Motion Sickness / veterinary*
  • Quinuclidines / therapeutic use*
  • Treatment Outcome
  • Vomiting / prevention & control
  • Vomiting / veterinary*


  • Antiemetics
  • Quinuclidines
  • maropitant